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Abstract
Background A recent study in children demonstrated that the
rs9939609 single-nucleotide polymorphism in the fat mass
and obesity (FTO) gene influences prospective weight gain,
however, only in those who were vitamin D-deficient. If this
might also be the case for Roux-en-Y gastric bypass (RYGB),
surgery-induced weight loss is however unknown. The objec-
tive of this study is to examine if the magnitude of RYGB
surgery-induced weight loss after 2 years depends on patients’
FTO rs9939609 genotype (i.e., TT, AT, and AA) and presur-
gery vitamin D status (<50 nmol/L equals deficiency).
Methods Before and at 24 months after RYGB surgery, BMI
was measured in 210 obese patients (mean BMI 45 kg/m2,
72% females). Serum 25-hydroxyvitamin D3 levels were also
repeatedly measured. Following surgery, vitamin D was sup-
plemented. Possible weight loss differences between geno-
types were tested with multiple linear regressions.
Results The per-allele effect of each FTO A-allele on exces-
sive BMI loss (EBMIL) was 3 % (P=0.02). When split by
baseline status, the EBMIL of vitamin D-deficient patients
carrying AA exceeded that of vitamin D-deficient patients
carrying TT by ~14 % (P=0.03). No such genotypic differ-
ences were found in patients without presurgery vitamin D
deficiency. Post-surgery serum levels of vitamin D did not
differ between groups.
Conclusions Our data suggest that presurgery vitamin D
levels influence the size of genotype effects of FTO
rs9939609 on RYGB surgery-induced weight loss in obese
patients.
Keywords VitaminD .FTO .RYGB .Weight loss .Bariatric
surgery
Introduction
Large cross-sectional studies have demonstrated that both
children and adults carrying the rs9939609 obesity A-allele
within an intron region of the fat- and obesity-associated gene
(FTO) exhibit higher BMI scores and are more often obese
than noncarriers [1–4]. In addition, a recent study involving 1,
088 children demonstrated that carriers of the FTO A-allele
gained more weight than noncarriers during a ~5-year obser-
vation period [5]. Complementing its important role for hu-
man body weight dynamics, some studies have demonstrated
that FTO rs9939609 (or proxy single-nucleotide polymor-
phisms) could also partially account for interindividual differ-
ences in weight loss upon Roux-en-Y gastric bypass (RYGB)
surgery [6–8]. Most interestingly, in the aforementioned study
investigating the impact of FTO on weight gain during child-
hood, genotypic differences in weight gain were only seen
between vitamin D-deficient children [5]. This suggests that
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the magnitude by which FTO influences human weight regu-
lation may partially depend on nutritional factors, comprising
vitamin D. However, as of yet, no study has investigated if the
influence of FTO on RYGB surgery-induced weight loss is
modulated by a patient’s presurgery vitamin D status. Thus,
the present study aimed at investigating if the FTO A-allele
predicts the 2-year weight loss response following RYGB
surgery and if this depends on a patient’s vitamin D status.
Importantly, following surgery, patients received vitamin D
supplements to avoid vitamin D undersupply.
Material and Methods
Patients
RYGB surgeries and follow-up investigations were performed
at the Interdisciplinary Obesity Center, St. Gallen, Switzer-
land. Before surgery, all patients (n=210, 72 % females) were
obese (BMI 45.2±0.43 kg/m2), and none had undergone any
kind of bariatric surgery procedure (e.g., gastric banding) be-
fore. Two different variants of RYGB surgery were per-
formed, i.e., proximal and distal RYGBs [5, 9]. In both pro-
cedures, the largest part of the stomach was transected, and a
small gastric pouch of about 20–30 mL was anastomized to
the proximal jejunum with the diameter of the pouch–jejunal
anastomosis standardized to be about 12 mm. In the proximal
RYGB procedure, the biliopancreatic limb was side to side
anatomized to the jejunum 150 cm distal from the pouch–
jejunal anastomosis (Roux-en-Y limb length, 150 cm). In the
distal RYGB procedure, the biliopancreatic limb was side to
side anatomized to the ileum 60 to 100 cm proximal from
Bauhin’s valve (common channel, 60–100 cm). The length
to the biliopancreatic limb was approximately 60 cm in the
proximal and 60 to 100 cm in the distal RYGB procedure.
Assessments
All participants were genotyped for the FTO-associated
single-nucleotide polymorphism (SNP) rs9939609 using
DNA isolated from whole blood with a custom Illumina
iSelect genotyping array (99.5 % success rate). Rs9939609
was confirmed to be in Hardy–Weinberg equilibrium.
At baseline (i.e., close to surgery), blood samples were
drawn in the morning (0800–1100h) after an overnight fast,
and serum 25-hydroxyvitamin D3 levels were determined by
high-performance liquid chromatography (Chromsystems, In-
struments & Chemicals GmbH, Munich, Germany). In gener-
al, serum levels of 25-hydroxyvitamin D3 lower than
50 nmol/L are defined as vitamin D deficiency [10]. Since
25-hydroxyvitamin D3 levels exhibit seasonal variation in
obese humans [11], the date where the blood was collected
was recorded. Post-surgery, all patients received standard oral
vitamin D3 supplements (1,200 IU/day). If serum levels of 25-
hydroxyvitamin D3 were below 50 nmol/L at follow-up in-
vestigations (i.e., at +3, +6, +9, +12, +18, and +24 months),
patients received additional intramuscular injection of 300,
000 IU every 3 months. Further preoperative preparations
and post-operative follow-up procedures are described in
more detail in [9].
At baseline and 24 months after RYGB surgery, height and
weight were measured with patients wearing light clothing
and no shoes. BMI was defined as weight (kg) divided by
height squared (m2). BMI was utilized to calculate relative
excessive BMI loss (EBMIL, cutoff for normal-weight
BMI=25 kg/m2) by the following equation [12]: 1−((initial
BMI−final BMI)/(initial BMI−25)))×100.
Statistics
A univariate general linear model (SPSS Statistics, version
21.0 for Windows, IBM, Chicago, IL, USA) was used to per-
form the regression analysis (assuming an additive model).
Predictors of interest were the three-level FTO rs9939609 ge-
notype (TT=0, AT/TA=1, AA=2), baseline serum vitamin D
levels, and their interaction term. In case of a significant inter-
action of FTO with baseline serum vitamin D levels, differ-
ences between genotypes were specified by post hoc
ANCOVA analysis. Linear mixed effect models were used
to investigate if FTO genotype groups, split by baseline vita-
min D status, would exhibit post-surgery differences in the
time course of serum levels of this micronutrient (i.e., com-
prising measurements at 3, 6, 12, 18, to 24 months). All anal-
yses were adjusted for age, sex, and BMI at baseline, unless
otherwise specified. Distal RYGB surgery is likely to cause
stronger malabsorption of vitamin D than the proximal sur-
gery procedure because the Y-connection is formed much
closer to the lower end of the small intestine. Given that the
vitamin D status was a variable of particular interest in our
study, we also covaried for the surgery type in our analyses.
The date where patients’ baseline session took place, compris-
ing the measurement of circulating 25-hydroxyvitamin D3
levels, was utilized as nominal variable in our statistical
models to account for seasonal variations of this vitamin
(subdivided into six time intervals, i.e., January–February,
March–April, May–June, etc.). Overall, a P value less than
0.05 was considered significant. Data are shown as mean ±
SEM, unless otherwise specified.
Results
As summarized in Table 1, approximately 70 % of our obese
patients carried at least one copy of the FTO A-allele. In ad-
dition, ~50 % of our obese patients were vitamin D-deficient
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at baseline. Following RYGB surgery, patients exhibited, on
average, an EBMIL of 83 %.
Association of FTO and Presurgery Vitamin D Status
with 2-Year Weight Loss Induced by RYGB Surgery
A univariate general linear model analysis revealed a positive
association between the 2-year EBMIL upon RYGB surgery
and FTO rs9939609 genotype (independent variable coeffi-
cient B(AA)=20.7, B(TA/AT)=13.3, B(TT)=0 (reference value),
P=0.02). The per-allele effect of each FTO A-allele on exces-
sive BMI loss (EBMIL) was 3 % (EBMIL, AA, 86.1±2.3 %;
TA/AT, 83.0±1.7 %; TT, 81.5±2.3 %; P=0.02). The strength
of this association, however, was influenced by presurgery
serum levels of 25-hydroxyvitamin D3 (P=0.04 for the inter-
action term BFTO*Vitamin D levels^). When split by their
baseline vitamin D status, AA patients who were vitamin D-
deficient exhibited a surgery-induced EBMIL that was ~14 %
higher than that of vitamin D-deficient TT carriers (P=0.03,
Fig. 1, left panel). In contrast, no such genotypic differences
were found in patients without presurgery vitamin D deficien-
cy (P=0.89), Fig. 1, right panel). Furthermore, no difference
in EBMIL between vitamin D-deficient TT carriers and
nondeficient TT carriers was seen (P=0.23). Finally, the pre-
surgery vitamin D status was not independently linked to
EBMIL (P=0.81).
Serum Levels of Vitamin D Prior to and After Surgery
Baseline serum levels of 25-hydroxyvitamin D3 revealed that
49.5 % of the patients in our cohort were vitamin D-deficient,
compared to 9.1 % who were vitamin D-deficient 2 years after
surgery (P<0.0001). A Fisher’s exact test showed that serum
25-hydroxyvitamin D3 levels after surgery did not differ be-
tween FTO genotype groups, when stratified by baseline
vitamin D status (P>0.05 at all time points post-surgery;
Table 2). As seen in Fig. 2, the mean vitamin D level increased
quickly in the vitamin D-deficient groups after surgery (and
initiation of vitamin D supplementation). Among the presur-
gery deficient patients, 30 % remained deficient at the first
follow-up visit (3 months post-op) and 11 % after 24 months.
Some patients with baseline levels above the deficiency cutoff
were deficient 24 months after surgery.
Discussion
Here, we show that patients who were vitamin D-deficient
before surgery exhibited a ~14 % higher RYGB surgery-
Table 1 Patients’ characteristics





Waist circumferencea (cm) 129±2
Diabetesa, n (% cohort) 17 (8.1)
Serum triglyceride levelsa (mmol/L) 1.8±0.1
Serum levels of vitamin D3a (nmol/L) 52.9±1.9
Vitamin D deficient, n (% cohort)
Pre-surgerya 104 (49.5)
Post-surgeryb 18 (9.1)




Surgery type, n (% cohort)
Distal RYGB 158 (75.2)
Proximal RYGB 52 (24.8)
BMIb (kg/m2) 28.6±3.9
EBMILb (%) 83.4±1.1
If not otherwise described, data are mean±SEM. Blood to determine
serum vitamin D levels and FTO rs9939609 genotype was collected in
a fasted state. Serum levels of 25-hydroxyvitamin D3 lower than 50 nmol/
L were defined as vitamin D deficiency. The presence of diabetes was
defined as use of oral hypoglycemic agents or insulin
BMI body mass index, EBMIL excessive BMI loss, SEM standard error
of mean, RYGB Roux-en-Y gastric bypass
a At baseline
bAt +24 months post-Roux-en-Y gastric bypass surgery





















Fig. 1 Percent excess BMI loss at 24 months post-surgery, split by
patients’ FTO rs9939609 genotype and presurgery vitamin D status. A
univariate general linear model was utilized to investigate if the FTO
rs9939609 genotype (i.e., AA, AT, or TT) predicts the magnitude of 2-
year weight loss following Roux-en-Y gastric bypass surgery and if this
depends on a patient’s baseline vitamin D status (assuming an additive
model). Baseline serum levels of 25-hydroxyvitamin D3<50 nmol/L
were defined as vitamin D deficiency. Data are shown as mean±SEM.
*P<0.05 for pairwise comparisons between groups
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induced weight loss when they carried two copies of the A-
allele in the fat mass and obesity (FTO) gene rs9939609,
compared to vitamin D-deficient patients who were homozy-
gous for the FTO T-allele. In contrast, no such differences
were found between genotypes when presurgery serum vita-
min D levels were above 50 nmol/L (i.e., their vitamin D
status was considered sufficient). These results could suggest
that presurgery vitamin D modulates the strength by which
FTO predicts RYGB surgery-induced weight loss in obese
humans. However, unless independent cohorts can replicate
our findings, caution is needed before generalizing our results
to patients undergoing other types of gastric bypass surgery
(e.g., gastric banding).
Large cross-sectional genome-wide association studies
have demonstrated that humans who carry the rs9939609 A-
allele have higher BMI scores than noncarriers [1–4]. Each
FTO risk allele increases BMI by 0.26–0.66 kg/m2, equivalent
to ~0.84–2.1 kg in body weight for a 1.80-m-tall person, and
the risk of obesity by 1.25–1.32 odds [13].With these findings
inmind, it might appear counterintuitive at first glance that our
study demonstrates that obese patients who carried the
rs9939609 A-allele exhibited the highest EBMIL after RYGB
surgery. However, our findings receive also some support
from the literature. For instance, in a study involving 520
obese patients, bariatric surgery-induced weight loss was
greatest in those who were carrying the rs9939609 A-allele
[6]. In addition, a previous nonsurgical study where obese
patients participated in a hypocaloric diet demonstrated that
Table 2 Number of vitamin D-deficient patients before and at +3, +6, +
9, +12, +18, and +24months post-Roux-en-Y gastric bypass surgery, split
by FTO rs9939609 genotype and presurgery vitamin D status
Months n (N) n (N) P value
TTa TAa AAa TT TA AA
Baseline 35 (35) 50 (50) 19 (19) 0 (22) 0 (48) 0 (36) –
+3 6 (17) 6 (24) 2 (12) 1 (8) 4 (25) 4 (15) 0.75
+6 1 (21) 2 (30) 1 (9) 1 (13) 1 (30) 1 (24) 0.88
+9 2 (19) 0 (32) 1 (10) 1 (12) 0 (29) 1 (22) 0.09
+12 2 (22) 2 (40) 1 (13) 1 (13) 1 (34) 1 (27) 0.84
+18 2 (23) 3 (40) 0 (14) 2 (15) 4 (39) 1 (25) 0.80
+24 5 (34) 4 (42) 1 (18) 2 (21) 3 (47) 3 (35) 0.87
Vitamin D deficiency was defined as serum levels of 25-hydroxyvitamin
D3<50 nmol/L. Note that following Roux-en-Y gastric bypass surgery,
all patients received standard oral vitamin D3 supplements (1,200 IU/
day). If serum levels of 25-hydroxyvitamin D3 were below 50 nmol/L
at follow-up visits, patients received additional intramuscular injection of
300,000 IU every 3 months. P values derive from Fisher’s exact test
n number of patients who were vitamin D-deficient, (N) number of pa-
tients for whom blood samples were available to determine their serum
vitamin D status
a Vitamin D-deficient patients before surgery (i.e., at baseline)


















































































Non-deficient, TT Non-deficient, TA Non-deficient, AA
Time (months) Time (months) Time (months)
Fig. 2 Serum levels of 25-hydroxyvitamin D3 in patients before and
after RYGB surgery, split by FTO rs9939609 genotype and presurgery
vitamin D status. Note that post-surgery, all patients received standard
oral vitamin D3 supplements (1,200 IU/day). If serum levels of 25-
hydroxyvitamin D3 were below 50 nmol/L (dashed lines) at follow-up
investigations (i.e., at +3, +6, +9, +12, +18, and +24 months), patients
received additional intramuscular injection of 300,000 IU every
3 months. Data are shown as mean±SEM
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carriers of the rs9939609 A-allele lost more body weight than
noncarriers during the intervention period [14]. However,
there are also studies that failed to show an impact of FTO
on weight loss response to dietary interventions. For instance,
in one study involving 204 Japanese women, FTO rs9939609
did not significantly change body weight or metabolic risk
factors in response to calorie restriction [15].
The main finding of our study is that patients with a pre-
operative vitamin D deficiency lost more weight following
RYGB surgery when they carried two copies of FTO
rs9939609 A-allele, than their homozygote counterparts did,
i.e., TT carriers who had a vitamin D deficiency. If replicated
by others, these findings suggest that the effect of FTO on
body weight regulation in humans is modulated by vitamin
D. In line with our observation, a previous genetic study dem-
onstrated that children who carried the FTOA-allele showed a
greater weight gain over 5 years compared to noncarriers,
however, only in those who were vitamin D-deficient [5]. This
suggests that vitamin D may possess biological properties that
can regulate the magnitude by which FTO or its genetic net-
work [16, 17] impacts body weight regulation in humans.
Vitamin D fulfills many biological functions in humans, com-
prising whole-body calcium metabolism [18]. A recent study
has shown that FTO interacts with three isoforms of calcium-
dependent protein kinase II: α, β, and γ. These protein ki-
nases phosphorylate a broad range of substrates, including
factors involved in the regulation of food intake and energy
homeostasis (e.g., BDNF, NPY1R) [19]. With this in mind, it
could be speculated that FTO A-allele carriers who were de-
ficient for vitamin D before RYGB surgery (a condition that is
expected to concur with a low calcium bioavailability)
showed the greatest weight loss after this procedure because
vitamin D supplementation exerted the strongest restorative
effect on mineral homeostasis in this genotype group. In ad-
dition to its effect on calcium homeostasis, vitamin D regu-
lates the transcription of numerous genes by activation of the
nuclear vitamin D receptor [18]. Thus, it could be speculated
that post-operative vitamin D supplementation regulated ei-
ther the transcription of FTO—which encodes a N6-RNA
demethylase [20]—or the transcription of genes that are func-
tionally connected with FTO (e.g. IRX3 or RPGRIP1L), or
both, and that these effects of post-operative vitamin D sup-
plementation on genetic regulation are strongest in vitamin D-
deficient FTO A-allele carriers. However, the reader must
keep in mind that these explanations are speculative and re-
quire further study.
Vitamin D can be synthesized by the human skin in re-
sponse to sunlight exposure. Thus, vitamin D deficiency could
also be a result of an inactive lifestyle, hallmarked by
sedentarism and home-based activities (e.g., TV watching)
[21–24]. Interestingly, a previous study involving patients
who underwent bypass surgery has shown that patients signif-
icantly increase the time spent in leisure activities after the
surgery [25]. With this in mind, it could be argued that RYGB
surgery may have increased the time spent in leisure activities
especially in those who were most sedentary before the sur-
gery, i.e., obese patients who were vitamin D-deficient. Of
note, physical activity has been shown to counteract the im-
pact of FTO on body weight in humans [26]. In the same way,
physical activity may boost the weight loss after RYGB sur-
gery in AA carriers. However, bearing in mind that our study
was of correlative nature, caution is needed before any firm
conclusion can be drawn about the mechanism through which
vitamin D may influence the impact of FTO on weight dy-
namics in humans.
As of yet, there is not much evidence for a beneficial effect
of vitamin D supplementation on body weight regulation in
humans. In a series of randomized controlled human studies
on vitamin D supplementation, only one involving 36,282
post-menopausal women demonstrated that the supplementa-
tion of calcium plus vitamin D had a minimal but consistent
favorable effect on weight (reviewed in [27]). However, these
studies did not control for FTO [27], which may explain why
the majority failed to show any beneficial effects of vitamin D
supplementation on weight. Alternatively, the putative lack of
efficacy of vitamin D supplementation in body weight reduc-
tion may also hint to vitamin D status as a simple marker of a
sedentary lifestyle. This notion would also be in accordance
with the previously found association of vitamin D deficiency
and metabolic disease like type 2 diabetes [28, 29].
Strengths and Limitations
Strengths of this study are that the study cohort was treated in
a highly standardized fashion in a single center, thereby large-
ly eliminating the biasing influence of distinct post-surgical
care. Furthermore, since respective data were systematically
collected, all analyses in our study could be adjusted for po-
tential confounders such as age, sex, BMI before surgery,
specific type of surgery, and season of vitamin measurement.
However, also several limitations of our study need to be
stated. Due to the 2-year follow-up time of our study, it re-
mains unclear whether the observed interplay of FTO and
vitamin D with weight loss persists over a longer follow-up
period. Another limitation is that possible confounds by other
factors, such as physical activity and the interplay ofFTOwith
other genes [30, 31], which were not considered in the present
analysis, cannot be excluded. Finally, generalization of our
findings to other age groups (e.g., obese children undergoing
bariatric surgery) or ethnic groups may not be appropriate.
Conclusions
Our study suggests that the presurgery vitamin D status of
patients undergoing RYGB surgery might be crucial for
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subsequent weight loss, especially in those who carry two
copies of the FTO rs9939609 A-allele. Our findings could also
offer a possible explanation as to why previous studies inves-
tigating the link between FTO and weight dynamics in
humans have produced somewhat inconsistent results [6, 14,
15], as the vitamin D status of participants before starting the
weight loss intervention may have not been taken into account
in these studies. Supporting this view, in our cohort, nearly
half of the obese patients exhibited a vitamin D deficiency
before surgery, demonstrating that this micronutrient deficien-
cy is abundant in obese people [32, 33].
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